multiple myeloma

News

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

News

J&J files Carvykti for earlier use in multiple myeloma

As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo

News

Leaked data shows stellar efficacy for J&J’s Carvykti

Johnson & Johnson was preparing to divulge the data from its eagerly-awaited CARTITUDE-4 trial of CAR-T therapy Carvykti later this year, but a leak of the data has gi

Oncology

Pfizer’s bispecific elranatamab and future oncological care

Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.

News

Trial sets up earlier use of J&J's Carvykti in myeloma

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

J&J bags first FDA approval for a GPRC5D drug

J&J files Carvykti for earlier use in multiple myeloma

Leaked data shows stellar efficacy for J&J’s Carvykti

Pfizer’s bispecific elranatamab and future oncological care

Trial sets up earlier use of J&J's Carvykti in myeloma

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

multiple myeloma

Editor's Picks